OKYO Pharma Limited (OKYO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
OKYO Pharma Limited Statistics
Share Statistics
OKYO Pharma Limited has 33.89M shares outstanding. The number of shares has increased by 1.96% in one year.
Shares Outstanding | 33.89M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 24.54M |
Failed to Deliver (FTD) Shares | 806 |
FTD / Avg. Volume | 1.28% |
Short Selling Information
The latest short interest is 215.78K, so 0.64% of the outstanding shares have been sold short.
Short Interest | 215.78K |
Short % of Shares Out | 0.64% |
Short % of Float | 0.88% |
Short Ratio (days to cover) | 6.58 |
Valuation Ratios
The PE ratio is -2563.69 and the forward PE ratio is null.
PE Ratio | -2563.69 |
Forward PE | null |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | -7.34 |
P/FCF Ratio | -4.55 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for OKYO Pharma Limited.
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.21, with a Debt / Equity ratio of 0.
Current Ratio | 0.21 |
Quick Ratio | 0.21 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | -0.01 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 0.27%.
Return on Equity (ROE) | 0% |
Return on Assets (ROA) | -0.01% |
Return on Capital (ROIC) | 0.27% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.10K |
Employee Count | 8 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 22.42 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -33.12% in the last 52 weeks. The beta is -3.36, so OKYO Pharma Limited's price volatility has been lower than the market average.
Beta | -3.36 |
52-Week Price Change | -33.12% |
50-Day Moving Average | 1.07 |
200-Day Moving Average | 1.19 |
Relative Strength Index (RSI) | 44.49 |
Average Volume (20 Days) | 62.80K |
Income Statement
Revenue | n/a |
Gross Profit | -7.51K |
Operating Income | -15.75K |
Net Income | -16.83K |
EBITDA | -15.75K |
EBIT | n/a |
Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 826.85K in cash and 0 in debt, giving a net cash position of 826.85K.
Cash & Cash Equivalents | 826.85K |
Total Debt | 0 |
Net Cash | 826.85K |
Retained Earnings | -142.52M |
Total Assets | - |
Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -9.49M and capital expenditures -3, giving a free cash flow of -9.49M.
Operating Cash Flow | -9.49M |
Capital Expenditures | -3 |
Free Cash Flow | -9.49M |
FCF Per Share | -0.32 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
OKYO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 0% |
FCF Yield | -27.06% |
Analyst Forecast
The average price target for OKYO is $7, which is 579.6% higher than the current price. The consensus rating is "Buy".
Price Target | $7 |
Price Target Difference | 579.6% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Scores
Altman Z-Score | null |
Piotroski F-Score | null |